Rapid and On-site Monitoring of Urinary Arsenic Metabolites

描述（由申请人提供）：Giner，Inc.提出了一种便携式，廉价，快速响应监测尿中砷的形态。尿液中排泄的砷物种反映了人类暴露于有毒砷，因此，该传感器将是一个有价值的生物监测工具，在医疗诊断和流行病学研究，允许确定砷暴露更快，更便宜的比传统的方法。提高监测接触的能力将产生积极的公共卫生结果，因为长期接触砷与癌症和心血管疾病等健康问题有关。第一阶段计划将开发一种监测器原型，能够直接电化学检测尿液中的砷（III）与先进的电极基板。将通过化学和电化学方法连续快速转化为砷（III），对其他重要砷物质和代谢物（砷[V]和单砷酸盐和二甲砷酸盐）进行定量，以获得尿液中有毒砷的总量。第一阶段项目可行性研究将包括用来自流行病学研究的真实的尿样验证α原型。第二阶段计划将产生一种实用、坚固和高度精确的设备，能够进行现场分析。 公共卫生相关性：提出了一种便携式、廉价、快速响应的尿中无机砷及其代谢产物形态分析监测仪。评估砷暴露的传统方法是时间密集型和成本高昂的，因此，这种低成本的现场监测将通过提高监测高危人群砷暴露的能力而产生积极的公共卫生结果。

DESCRIPTION (provided by applicant): Giner, Inc. proposes a portable, inexpensive, and rapid-response monitor for arsenic speciation in urine. Arsenic species excreted in urine are reflective of human exposure to toxic arsenic, and therefore this sensor will be a valuable biomonitoring tool in medical diagnostics and epidemiological studies by allowing determination of arsenic exposure faster and less expensive than traditional methods. Improved capability of monitoring exposure will have positive public health outcomes, as chronic exposure to arsenic is associated with health problems including cancer and cardiovascular disease. The Phase I program will develop a monitor prototype capable of direct electrochemical detection of arsenic (III) in urine with an advanced electrode substrate. Quantification of other important arsenic species and metabolites (arsenic [V] and mono- and dimethyl arsinate) will be performed by sequential and rapid conversion to arsenic (III) via chemical and electrochemical methods to obtain the total amount of toxic arsenic in urine. The phase I program feasibility studies will include validation of the alpha prototype with real urine samples from epidemiological studies. The phase II program will result in a practical, robust, and highly accurate device capable of on-site analysis. PUBLIC HEALTH RELEVANCE: A portable, inexpensive, and rapid-response monitor for speciation analysis of inorganic arsenic and arsenic metabolites species in urine is proposed. Traditional methods of assessing arsenic exposure are time-intensive and cost-prohibitive, and therefore such low cost onsite monitor will have positive public health outcomes by improving ability to monitor arsenic exposure in at-risk populations.